Sucralfate Pellets
(Product under development)
Sucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.Brand names include Sucramal in Italy; Carafate in U.S.A.; Pepsigard, Sucral, Sucrafil, Hapifate in India; Sutra in parts of South-East Asia; Sulcrate in Canada; Ulsanic in South Africa; and Antepsin in Turkey. Sucralfate is also used for the treatment of gastroesophageal reflux disease (GERD) and stress ulcers.
Unlike the other classes of medications used for treatment of peptic ulcers, sucralfate is a sucrose sulfate-aluminium complex that binds to the mucosa, thus creating a physical barrier that impairs diffusion of hydrochloric acid in the gastrointestinal tract and prevents degradation of mucus by acid.
It also stimulates bicarbonate output and acts like an acid buffer with cytoprotective properties. Sucralfate was approved by the U.S. Food and Drug Administration (FDA) in 1981.
Available Form:
Sucralfate Pellets
Sucralfate Granules
Umang Pharmatech equipments used for production of Sucralfate Pellets:
Drug Layering, Fluid Bed Dryer, Fluid Bed Coater, Sifter & Blender, Extruder and Twin spheronizer.
| Sucralfate Pellets Systematic (IUPAC) Name |
Sucralfate Pellets Identifiers |
Sucralfate Pellets Chemical data |
||||||||||||||||||
| Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum |
|
|
* All transactions are carried out in conformity with patent laws applicable in the user country. Active pharmaceutical ingredients or formulations thereof will not be supplied in countries where the same is under patent protection except as and if permitted under law of the country for research and development purposes only.
